A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection.

Trial Profile

A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Gram-negative infections; Gram-positive infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 03 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment.
    • 14 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top